Relugolix meaningfully reduces endometriosis pain
The Phase III trials saw 75 percent of women in…
The Phase III trials saw 75 percent of women in the relugolix combination therapy group achieve a reduction in dysmenorrhea (menstrual pain), compared with 30 percent or less of women in the placebo groups.